NewAmsterdam Pharma Company

Filter

År

Typ

Språk

Rensa

2025-05-08 14:00:00 NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results 19,27 EUR | +1,85%

2025-05-07 13:15:00 NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 18,92 EUR | -0,42%

2025-05-02 22:01:00 NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 20,03 EUR | 0,00%

2025-04-30 14:00:00 NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress 19,13 EUR | +3,13%

2025-04-17 22:01:00 NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors 16,34 EUR | +1,93%

2025-04-04 22:01:00 NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 15,81 EUR | -12,17%

2025-02-26 14:00:00 NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update 19,71 EUR | +10,23%

2025-02-25 14:00:00 NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March 17,88 EUR | +2,00%

2025-02-07 22:01:00 NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 20,19 EUR | -4,31%

2025-01-29 14:00:00 NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference 20,78 EUR | -3,12%

2025-01-09 21:38:33 NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2024-12-13 23:16:28 NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares 24,69 EUR | -1,59%

2024-12-12 03:37:09 NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants 25,09 EUR | -1,88%

2024-12-10 22:34:49 NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants 26,19 EUR | +41,41%

2024-12-10 13:00:00 NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia 26,19 EUR | +41,41%

2024-12-06 22:01:00 NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 18,35 EUR | +1,55%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

NewAmsterdam Pharma Company

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden